Full Press Release Details
Therapeutics Regains Compliance with Nasdaq Listing Requirements
YORK and CLEVELAND, July 20, 2022 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq
Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the minimum bid price requirement under
Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market. In order to regain compliance
with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10
consecutive trading days. That requirement was met on July 18, 2022.
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's
lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa
in Phase 3 development. The Company's development portfolio also features AAV-based gene therapies for ophthalmic diseases with
high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety
of devastating diseases. Abeona's fully integrated cell and gene therapy cGMP manufacturing facility produces EB-101 for the pivotal
Phase 3 VIITAL study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information,
visit www.abeonatherapeutics.com.
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as "may," "will," "believe," "estimate,"
"expect," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances),
which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited
to, the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition; continued interest in our rare
disease portfolio; our ability to potentially commercialize our EB-101 product candidate; our ability to enroll patients in clinical
trials; the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies; the impact of competition;
the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions;
risks associated with data analysis and reporting; reducing our operating expenses and extending our cash runway; our ability to execute
our operating plan and achieve important anticipated milestones; and other risks disclosed in the Company's most recent Annual
Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation
to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press
release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
VP, Investor Relations and Corporate Communications